296 related articles for article (PubMed ID: 33910760)
21. Measurement of procarboxypeptidase U (TAFI) in human plasma: a laboratory challenge.
Willemse JL; Hendriks DF
Clin Chem; 2006 Jan; 52(1):30-6. PubMed ID: 16299049
[TBL] [Abstract][Full Text] [Related]
22. Proteolytic activation of purified human procarboxypeptidase U.
Schatteman KA; Goossens FJ; Scharpé SS; Hendriks DF
Clin Chim Acta; 2000 Feb; 292(1-2):25-40. PubMed ID: 10686274
[TBL] [Abstract][Full Text] [Related]
23. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
Antovic JP; Blombäck M
Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
[TBL] [Abstract][Full Text] [Related]
24. A role for procarboxypepidase U (TAFI) in thrombosis.
Willemse JL; Hendriks DF
Front Biosci; 2007 Jan; 12():1973-87. PubMed ID: 17127436
[TBL] [Abstract][Full Text] [Related]
25. Procarboxypeptidase U (TAFI) and the Thr325Ile proCPU polymorphism in patients with hereditary mucocutaneous hemorrhages.
Matus V; Willemse J; Quiroga T; Goycoolea M; Aranda E; Panes O; Pereira J; Hendriks D; Mezzano D
Clin Chim Acta; 2009 Mar; 401(1-2):158-61. PubMed ID: 19038242
[TBL] [Abstract][Full Text] [Related]
26. Carboxypeptidase U at the interface between coagulation and fibrinolysis.
Schatteman K; Goossens F; Leurs J; Verkerk R; Scharpé S; Michiels JJ; Hendriks D
Clin Appl Thromb Hemost; 2001 Apr; 7(2):93-101. PubMed ID: 11292199
[TBL] [Abstract][Full Text] [Related]
27. Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
Krysiak R; Okopień B; Herman Z
Drugs; 2003; 63(17):1821-54. PubMed ID: 12921488
[TBL] [Abstract][Full Text] [Related]
28. Thrombin-activatable fibrinolysis inhibitor is activated in vivo in a baboon model of Escherichia coli induced sepsis.
Kim PY; Kim PY; Taylor FB; Nesheim ME
J Thromb Thrombolysis; 2012 May; 33(4):412-5. PubMed ID: 22228479
[TBL] [Abstract][Full Text] [Related]
29. Rosuvastatin use increases plasma fibrinolytic potential: a randomised clinical trial.
Schol-Gelok S; de Maat MPM; Biedermann JS; van Gelder T; Leebeek FWG; Lijfering WM; van der Meer FJM; Rijken DC; Versmissen J; Kruip MJHA
Br J Haematol; 2020 Sep; 190(6):916-922. PubMed ID: 32301122
[TBL] [Abstract][Full Text] [Related]
30. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome.
Brouns R; Heylen E; Willemse JL; Sheorajpanday R; De Surgeloose D; Verkerk R; De Deyn PP; Hendriks DF
J Thromb Haemost; 2010 Jan; 8(1):75-80. PubMed ID: 19874466
[TBL] [Abstract][Full Text] [Related]
31. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo- controlled, 12-week study in early postmenopausal women.
Post MS; Hendriks DF; Van Der Mooren MJ; Van Baal WM; Leurs JR; Emeis JJ; Kenemans P; Stehouwer CD
J Intern Med; 2002 Mar; 251(3):245-51. PubMed ID: 11886484
[TBL] [Abstract][Full Text] [Related]
32. Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy?
Willemse JL; Heylen E; Nesheim ME; Hendriks DF
J Thromb Haemost; 2009 Dec; 7(12):1962-71. PubMed ID: 19719827
[TBL] [Abstract][Full Text] [Related]
33. Thrombin activatable fibrinolysis inhibitor.
Declerck PJ
Hamostaseologie; 2011 Aug; 31(3):165-6, 168-73. PubMed ID: 21629966
[TBL] [Abstract][Full Text] [Related]
34. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
Bajzar L; Nesheim ME; Tracy PB
Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
[TBL] [Abstract][Full Text] [Related]
35. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Heylen E; Miljic P; Willemse J; Djordjevic V; Radojkovic D; Colovic M; Elezovic I; Hendriks D
Thromb Res; 2009 Sep; 124(4):427-32. PubMed ID: 19195685
[TBL] [Abstract][Full Text] [Related]
36. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma.
Kim PY; Foley J; Hsu G; Kim PY; Nesheim ME
Anal Biochem; 2008 Jan; 372(1):32-40. PubMed ID: 17967438
[TBL] [Abstract][Full Text] [Related]
37. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.
Walker JB; Bajzar L
J Biol Chem; 2004 Jul; 279(27):27896-904. PubMed ID: 15128744
[TBL] [Abstract][Full Text] [Related]
38. Measurement of carboxypeptidase U (active thrombin-activatable fibrinolysis inhibitor) in plasma: Challenges overcome by a novel selective assay.
Heylen E; Van Goethem S; Augustyns K; Hendriks D
Anal Biochem; 2010 Aug; 403(1-2):114-6. PubMed ID: 20371219
[TBL] [Abstract][Full Text] [Related]
39. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism.
Leurs J; Nerme V; Sim Y; Hendriks D
J Thromb Haemost; 2004 Mar; 2(3):416-23. PubMed ID: 15009457
[TBL] [Abstract][Full Text] [Related]
40. Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
Seljeflot I; Tonstad S; Hjermann I; Arnesen H
Thromb Res; 2002 Feb; 105(4):285-90. PubMed ID: 12031821
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
